The First Description of Monozygotic Twin Females Discordant for the Craniofrontonasal Syndrome Phenotype and the Report of Four Novel Pathogenic Variants in the *EFNB1* Gene

Ewelina Bukowska-Olech (ewe.olech@gmail.com)  
Uniwersytet Medyczny imienia Karola Marcinkowskiego w Poznaniu  
https://orcid.org/0000-0003-0509-1696

Paweł Gawliński  
Department of Medical Genetics, Institute of Mother and Child, Warsaw

Anna Jakubiuk-Tomaszuk  
Department of Pediatric Neurology and Rehabilitation, Medical University of Białystok; Medical Genetics Unit, Mastermed Medical Center, Białystok

Maria Jędrzejewska  
Children's Health Ireland at Crumlin Department of Clinical Genetics

Ewa Obersztyn  
Department of Medical Genetics, The Children's Memorial Health Institute, Warsaw

Michał Piechota  
Centers for Medical Genetics GENESIS, Poznań

Marta Bielska  
Department of Pediatrics, Hematology, Oncology and Diabetology, Medical University of Łódź, Łódź

Aleksander Jamsheer  
Uniwersytet Medyczny im Karola Marcinkowskiego w Poznaniu: Uniwersytet Medyczny imienia Karola Marcinkowskiego w Poznaniu

Research

**Keywords:** monozygosity, discordant phenotype, EFN1, ephrin B1, coronal craniosynostosis, custom targeted next-generation sequencing

**Posted Date:** April 6th, 2021

**DOI:** https://doi.org/10.21203/rs.3.rs-386853/v1

**License:** This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Background: Craniofrontonasal syndrome (CFNS) is a rare X-linked disorder that results from pathogenic variants in the EFNB1 gene. The syndrome paradoxically presents with greater severity of the symptoms in heterozygous females than hemizygous males.

Results: Our primary finding was the description of monozygotic twins, i.e., patients 5 & 6, discordant for the CFNS phenotype. Intriguingly, patient 5 presented classical CFNS gestalt, whereas patient 6 manifested only very subtle craniofacial features, not resembling CFNS. Besides, we have expanded the mutational spectrum of the EFNB1 gene through reporting four novel pathogenic variants – p.(Trp12*), p.(Cys64Phe), p.(Tyr73Metfs*86), p. (Glu210*). All those alterations were found applying either targeted NGS of a custom gene panel or PCR followed by Sanger sequencing and evaluated using in silico predictors. Lastly, we have also expanded the CFNS phenotypic spectrum by describing in patient 3 novel features of the syndrome, such as bifid hallux, bicornuate uterus, and abnormal right ovary segmented into six parts.

Conclusions: We have described the unreported so far differences of the clinical phenotype in the monozygotic twin patients 5 & 6 harbouring an identical p.(Glu210*) variant located in the EFNB1 gene. With our finding, we have pointed to an unusual phenomenon of mildly affected females with CFNS, who may not manifest features suggestive of the syndrome. Consequently, this study may be valuable for geneticists consulting patients with craniofacial disorders.

Introduction

Craniofrontonasal syndrome (CFNS; MIM: 304110) is a rare X-linked disorder that inherits in a paradoxical manner, exceptionally presenting greater severity of symptoms in heterozygous females than hemizygous males (1, 2). The clinical picture in the affected females encompasses coronal craniosynostosis (CS), frontal bossing, hypertelorism, depressed nasal bridge, bifid nose, craniofacial asymmetry, downslanting palpebral fissures, frizzy and curly hair, syndactyly and longitudinally ridged fingernails. Intriguingly, many symptomatic hemizygous men show merely hypertelorism with no other congenital anomalies of major facial dysmorphism (3, 4).

Wieacker and Wieland in 2005 explained the above paradox as a cellular interference, which assumes that due to a random X-inactivation, heterozygous females are uniquely mosaic and therefore have both functional and nonfunctional ephrin-B1, a protein which is encoded by the EFNB1 gene (Wieland et al., 2004; Wieacker and Wieland, 2005). These two ephrin-B1 forms' coexistence affects the adhesion and sorting of cells, disrupting normal embryological development (6, 7). Further reports describing more severely affected males, who all were mosaic for deleterious variants in the EFNB1, strengthen the hypothesis about the described pathomechanism's biological relevance (8). However, the precise molecular explanation for this phenomenon remains not yet fully understood (7).

Cohort description

We recruited four sporadic female individuals (patients 1–4) and one familial case consisting of two female individuals (patient 5 & 6), out of whom all but one, i.e. patient 6, presented phenotypic features suggestive of CFNS.
Results

Clinical report

We recruited six female cases who, out of whom all but one, i.e. patient 6, presented with phenotypic characteristics suggestive for CFNS. The comparison of all clinical features noted in our cohort was outlined in Table 1, whereas the photographic documentation of facial dysmorphism and hand and foot anomalies was shown in Supplementary Fig. 1. Our study's primary finding was the description of monozygotic twins, i.e., patients 5 & 6, discordant for the CFNS phenotype. Patient 5 presented with classical CFNS dysmorphia such as corse facial feature, CS and syndactyly (Fig. 1a-d), whereas patient 6 manifested only very subtle craniofacial features not resembling CFNS (Fig. 1e).
Table 1
Clinical manifestations of seven patients with craniofrontonasal syndrome. ID – intellectual disability HPO no. – Human Phenotype Ontology database number identification for phenotypic abnormality (Köhler et al., 2014); Symbols: +, feature present; (+); −, feature absent; nd, no data; na, not applicable.

| #  | Features                              | HPO no.       | patient 1          | patient 2          | patient 3       | patient 4       | patient 5       | patient 6       |
|----|---------------------------------------|---------------|--------------------|--------------------|-----------------|-----------------|-----------------|-----------------|
| 1  | Variant: NM_004429.4                  |               | c.35G > A          | c.191G > T         | c.216del        | c.451G > A      | c.628G > T      | c.628G > T      |
| 2  | Sex                                   |               | F                  | F                  | F               | F               | F               | F               |
| 3  | Relationship                          |               | na                 | na                 | na              | na              | Twin 1          | Twin 2          |
| 4  | Hypertelorism                         | HP:0000316    | +                  | +                  | +               | +               | +               | +               |
| 5  | Epicanthus                            | HP:0000286    | -                  | +                  | +               | -               | +               | -               |
| 6  | Down-slanting palpebral fissures     | HP:0000494    | Up-slanting palpebral fissures | -                  | up-slanting palpebral fissures | +               | -               | -               |
| 7  | Anteverted nares                      | HP:0000463    | +                  | +                  | +               | +               | +               | +               |
| 8  | Depressed nasal bridge                | HP:0005280    | +                  | +                  | prominent nasal bridge | +               | +               | +               |
| 9  | Midline nasal groove                  | HP:0004112    | +                  | +                  | +               | +               | +               | -               |
| 10 | Abnormality of the pinna              | HP:0000377    | + thick helix      | -                  | prominent antihelix | +               | +               | -               |
| 11 | Low-set ears                          | HP:0000369    | -                  | +                  | +               | +               | +               | +               |
| 12 | Coarse facial feature                 | HP:0000280    | +                  | +                  | +               | +               | +               | +               |
| 13 | Midface retrusion                     | HP:0011800    | +                  | +                  | +               | +               | -               | -               |
| 14 | Micrognathia                          | HP:0000347    | +                  | -                  | -               | +               | +               | +               |
| 15 | High palate                           | HP:0000218    | +                  | +                  | +               | +               | -               | -               |
| 16 | Anterior open bite                    | HP:0200095    | +                  | +                  | +               | +               | -               | -               |
| 17 | Cleft upper lip                       | HP:0000204    | -                  | -                  | -               | -               | -               | -               |
| 18 | Bilateral cleft lip and palate        | HP:0002744    | -                  | -                  | -               | -               | -               | -               |
| 19 | Ankyloglossia                         | HP:0010296    | -                  | ?                  | +               | -               | -               | -               |
| 20 | Hoarse voice                          | HP:0001609    | -                  | ?                  | +               | -               | *               | *               |
| 21 | Short neck                            | HP:0000470    | +                  | +                  | +               | +               | -               | +               |

* – the symptom cannot be assessed (the patient too young)
| #  | Features                                      | HPO no.          | patient 1 | patient 2 | patient 3 | patient 4 | patient 5 | patient 6 |
|----|----------------------------------------------|------------------|-----------|-----------|-----------|-----------|-----------|-----------|
| 22 | Small anterior fontanelle                    | HP:0000237       | -         | ?         | ?         | ?         | -         | -         |
| 23 | Dysgenesis of the corpus callosum            | HP:0006989       | ?         | +         | (posterior part) | -         | ?         | ?         |
| 24 | Agenesis of the corpus callosum              | HP:0001274       | ?         | +         | -         | +         | ?         | ?         |
| 25 | Plagiocephaly                                | HP:0001357       | -         | +         | -         | +         | +         | -         |
| 26 | Craniosynostosis                             | HP:0001363       | -         | +         | +         | +         | +         | -         |
| 27 | Global developmental delay                   | HP:0001263       | +         | -         | +         | +         | -         | -         |
|    |                                              |                  |           |           | Mild ID   | Mild ID   |           |           |
| 28 | Brachydactyly                                | HP:0001156       | +         | -         | +         | -         | +         | +         |
| 29 | Broad thumb                                  | HP:0011304       | +         | -         | duplicated thumb | -         | +         | -         |
| 30 | Toe syndactyly                               | HP:0001770       | -         | + (feet)  | -         | -         | + (feet)  | -         |
|    | Finger syndactyly                            | HP:0006101       |           |           |           |           |           |           |
| 31 | Longitudinal ridging of toenails             | HP:0001807       | +         | +         | +         | ?         | +         | +         |
| 32 | Longitudinal ridging of fingernails          | HP:0001807       | +         | +         | +         | +         | +         | +         |
| 33 | Shoulder girdle muscle atrophy               | HP:0003724       | -         | +         | +         | ?         | *         | *         |
| 34 | Limited shoulder movement                    | HP:0006467       | -         | ?         | +         | -         | *         | *         |
| 35 | Low-set nipples                              | HP:0002562       | +         | +         | +         | -         | -         | -         |

* – the symptom cannot be assessed (the patient too young)

Patient 3 presented some novel for CFNS clinical features such as a bifid hallux (Supplementary Fig. 1d) bicornuate uterus, abnormal right ovary segmented into six parts by five serpentine-like constrictions, with the largest ovary part of 1.5 cm, while the smallest one of 0.5 cm in diameter. To our best knowledge, this phenotype has not been reported in CFNS yet. She also showed congenital horizontal nystagmus, alternating divergent strabismus, defects of the genitourinary system, including horseshoe kidney, and not noted in CFNS thus far.

**Patient 5**
Patient 5 was a girl born in the 38th week of gestation from 4th pregnancy twined to unrelated healthy parents (Figure 1f). The pregnancy history was unknown because patient 5 was adopted. Her body mass was 2370 g (<3rd percentile), length 49 cm (<3rd percentile), Apgar score was 8-10-10 at 1',3' and 5'. She was referred for dysmorphic evaluation at 1st month of age. She had a coarse face, plagiocephaly, CS, micrognathia, a small anterior fontanel, significant hypertelorism, bilateral epicanthal folds, bilateral low-set ears, flat nasal bridge, anteverted nares, and a midline crease of the nasal tip. Brachydactyly, syndactyly of toes and longitudinal ridging of a finger- and toenails were also observed. On examination at the age of 5.5 months, she presented with a weight of 6110 g (<3rd centile) and head circumference of 37.8 cm (<3rd centile).

Patient 6

Patient 6 was a girl born in the 38th week of gestation from 4th pregnancy twined to unrelated healthy parents (Figure 1f). The pregnancy history was unknown because patient 6 was adopted. Her body mass was 2330 g (<3rd percentile), length 50 cm (<3rd percentile), Apgar score was 8-8-9 at 1', 3', 5' and 10'. She was referred for dysmorphic evaluation at 4th month of age since her twin sister obtained a diagnosis of CFND. She had coarse facial features, anteverted nares, depressed nasal bridge, short neck and longitudinal ridging of a finger- and toenails.

Targeted next-generation sequencing (NGS) and Sanger sequencing

gDNA (isolated from peripheral blood lymphocytes) of Patients 1 & 5 was subject to targeted NGS of a custom gene panel that revealed two novel heterozygous variants in the EFNB1 gene – c.35G>A p.(Trp12*) and c.628G>T p.(Glu210*), respectively (Figure 2a). The presence of both alterations was confirmed by Sanger sequencing. Patients 2-4 were screened before the advent of the NGS method. Thus the molecular diagnosis was achieved by Sanger sequencing on gDNA isolated from peripheral blood lymphocytes, which revealed the presence of the following three heterozygous alterations out of which two were novel – c.191G>T p.(Cys64Phe), c.216del p. (Tyr73Metfs*86). In contrast, one variant has been previously reported c.451G>A p.(Gly151Ser) (HGMD no: CM041297) (Figure 2b). The family history of patient 5 showed that she has a twin sister who, despite the lack of typical CFNS symptoms, underwent targeted PCR and Sanger sequencing. We evaluated the pathogenicity of missense variants in silico applying multiple online prediction tools including Polyphen-2, SIFT, CADD, MutationTaster and other resources such as DANN, FATHMM-MKL, LRT, BayesDel addAF, BayesDel noAF, GERP, PhyloP100, PhastCons integrated into either VarSome online tool or Alamut® Visual software product. The classification of all variants was performed following the American College of Medical Genetics and Genomics (ACMG) guidelines (Table 2). Applying SWISS-MODEL, we have visualized in 3D both wild type and mutated missense alterations in the ephrin-B1, i.e. p.(Cys64Phe) and p.(Gly151Ser) (13).
Table 2

The overview of missense and nonsense variants found in the EFNB1 gene through MutationTaster, Varsome online tools (obtained on 2\textsuperscript{nd} November 2020) and Alamut\textsuperscript{®} Visual software (obtained on 10\textsuperscript{th} November 2020)

| Coding DNA level (NM_004429.4) | patient 1 | patient 2 | patient 4 | patient 5 & 6 |
|----------------------------------|-----------|-----------|-----------|--------------|
| c.35G>A                          |           |           |           | c.628G>T     |
| gDNA level                       |           |           |           | g.11092      |
| g.815G>A                         |           |           |           |             |
| chromosomal level (GRCh38)       |           |           |           |             |
| chrX:68829811G>A                 |           |           |           |             |
| Protein level NM (NP_)           |           |           |           |             |
| p.Trp12Ter                       |           |           |           |             |
| Exon                             | 1         | 2         | 3         | 4            |
| HGMD (v15.11) no.                | Not reported | Not reported | CM041297 | Not reported |
| dbSNP rs number                  | rs1482772814 | Not reported | rs28936069 | Not reported |
| gnomAD (v2.1.1)                  | Not reported | Not reported | Not reported | Not reported |
| 1000 Genomes                     | Not reported | Not reported | Not reported | Not reported |
| ACMG classification              | Pathogenic | Likely pathogenic | Likely pathogenic | Pathogenic |
| SIFT (v6.2.0)                    | n.d.      | Deleterious | Deleterious | n.d.         |
| PolyPhen-2 (v2)                  | n.d.      | Probably damaging | Probably damaging | n.d.         |
| DANN (v2014)                     | 0.9954    | 0.9935    | 0.9989    | 0.9969       |
| FATHMM-MKL (dbNSFP v4.1)         | Damaging  | Damaging  | Damaging  | Damaging     |
| LRT (dbNSFP v4.1)                | Neutral   | Deleterious | Deleterious | Neutral     |
| BayesDel addAF (v4.1)            | Damaging  | Damaging  | Damaging  | Damaging     |
| BayesDel noAF (v4.1)             | Damaging  | Damaging  | Damaging  | Damaging     |
| MutationTaster (v2013)           | Disease causing | Disease causing | Disease causing | Disease causing |

Zygosity analysis

The monozigosity of twin patient 5 & 6 was confirmed based on an analysis of 33 STR markers localized on 13, 18, 21, X and Y chromosomes.
X chromosome inactivation (XCI) assay

We detected random XCI in twin patient 6 (46% vs. 54%), who manifested facial features unsuggestive for CFNS, whereas non-random XCI (84% vs. 16%) in twin patient 5, who showed a classical CFNS facial phenotype.

Face2Gene analysis

The craniofacial phenotype of patient 6 was assessed using Face2Gene online available tool. Among the suggested 30 different syndromes, CFNS was not listed by the algorithm. However, the first five proposed diagnoses were as follows – Cornelia de Lange syndrome, Costello syndrome, Megalencephaly-Capillary Malformation-Polymicrogyria Syndrome, Alpha-Thalassemia/mental Retardation Syndrome and CHARGE syndrome. On the contrary, the phenotype of patient 5 was correctly identified as CFNS (listed as second).

Discussion

Although monozygotic twins originate from a single zygote and share the same genetic material and similar intrauterine environment, they occasionally may show discordant phenotypes of monozygotic disorder. The differences in clinical phenotype can be explained through at least several mechanisms such as epigenetic factors, an asymmetric split of the embryo, discordant cell differentiation or abnormalities in placental blood flow (14–16). Surprisingly, here we have diagnosed monozygotic twin patients, i. e. patient 5 & 6, who presented with highly variable severity of the CFNS symptoms. Both individuals carried the same p.(Glu210*) pathogenic EFNB1 variant and identical germline genetic information. In patient 5, we noted a typical female presentation of CFNS (Table 1, Fig. 1a-d). In contrast, in patient 6, we only detected mild facial anomalies unsuggestive for CFNS, including anteverted nares, depressed nasal bridge, low-set ears, coarse facial features, micrognathia and short neck (Table 1 and Fig. 1e). Besides, the craniofacial phenotype of patient 6 was analyzed using Face2Gene, which did not match CFNS among the possible dysmorphological diagnoses.

Mild clinical features in female individuals with CFNS are rather unusual. As mentioned before, CFNS inherits paradoxically and presents more severe clinical symptoms in females, who harbour the heterozygous EFNB1 variants in comparison to hemizygous males. Furthermore, rarely reported mosaic male individuals are more severely affected than their hemizygous counterparts. This is because other ephrin family members can presumably substitute the complete lack of ephrin-B1 in purely hemizygous males (3, 7, 17). In the medical literature, we have found merely one description of mildly affected CFNS female patient. Twigg et al. reported a familial case (family no. 3217) heterozygous for a missense pathogenic variant p.(Pro54Leu), in which one of the affected females had minimal clinical manifestations of CFNS. However, this patient was shown to have a lower mutation level in the hair roots and buccal swab (2). In our case, we were unable to check for the mosaicism in mesoderm or ectoderm-derived cell lines, although the level for the causative variant in blood cells reached 50% of reads, being unsuggestive of somatic mosaicism.

Except for mosaicism in other than blood cells, one may suspect the presence of additional modifiers of the phenotype, including epigenetic factors (18–20). To check whether the variable severity of CFNS in both twin females resulted from skewed X chromosome inactivation, we performed XCI testing. We hypothesized that similar to male patients who show minimal CFNS symptoms, our mildly affected twin sister may have a highly preferential expression of the EFNB1 from a single gene copy, resembling its status in hemizygosity. To our surprise, we demonstrated unequal XCI in the severely affected twin patient 5 (84% vs. 16%), and almost random
X inactivation in the mildly affected twin patient 6 (46% vs. 54%). Our finding, therefore, suggests that skewed X inactivation cannot account for the mild presentation of CFNS in one of our twin sisters and probably other mildly affected female individuals. Recently, another research group did not find evidence for preferential XCI or a distinct correlation between XCI ratios in a group of familial X-linked hypohidrotic ectodermal dysplasia patients showing variable disease manifestation (21). Hence our result strengthens the above conclusion regarding the presence of additional yet undetected modifying factors resulting in discordant phenotype in X-linked disorders.

The second result of our study is the expansion of the *EFNB1* gene mutational spectrum. Here, we have described three additional novel variants located in the *EFNB1* gene – p.(Trp12*), p.(Tyr73Metfs*86), p.(Glu210*) and consequently increased the total number of CFNS-associated pathogenic variants to 123. All newly identified alterations were found applying either targeted NGS of a custom gene panel or PCR followed by Sanger sequencing. Subsequently, we evaluated the pathogenicity of the detected variants using *in silico* predictors (Table 2). We have also compared the phenotypic presentation of the six CFNS-affected individuals, all of whom were females (Table 1). Lastly, we have also broadened the phenotypic spectrum of CFNS syndrome, as we reported new features present in patient 3, such as a bifid hallux, bicornuate uterus and abnormal right ovary segmented into six parts.

**Conclusions**

First of all, we have pointed to an unusual phenomenon of mildly affected females with CFNS, who may not manifest features suggestive of the syndrome. As a consequence, this study may be valuable for clinical geneticists consulting patients with craniofacial disorders and who potentially may overlook such individuals. Second, we excluded skewed XCI pattern as a cause of discordant phenotype in monozygotic twins described here. Our study strengthens the recent conclusion regarding the presence of additional yet undetected modifying factors resulting in X-linked disorders’ discordant phenotype. Finally, we have expanded the mutational spectrum of the *EFNB1* gene by reporting three other novel pathogenic variants causing CFNS.

**Methods**

**Targeted NGS**

We designed and applied the custom On-Demand AmpliSeq (ThermoFisher Scientific) panel targeting 37 genes related to craniofacial disorders (9,10). We constructed the barcoded gDNA libraries according to the manufacturer’s sample preparation protocol (Ion AmpliSeq Library Kit 2.0; On-Demand Panels) and subsequently sequenced them on the Ion Torrent S5 platform using the Ion 530™ or 540™ Chip.

**PCR and Sanger sequencing**

PCR followed by Sanger sequencing was used to validate variants detected through targeted NGS (patient 1 & 5) and screen the coding sequence of the *EFNB1* gene (patients 2-4). Besides, we performed targeted Sanger sequencing in the twin sister of patient 6 (targeted analysis of exon 4). We designed specific primers (Supplementary Table 1) using Primer3 tool v. 0.4.0. The PCR reactions and PCR product purifications were carried out following standard protocols. Next, Sanger sequencing was performed on an automated sequencer Applied Biosystems Prism 3700 DNA Analyzer using dye-terminator chemistry kit v.3, ABI 3130XL. Finally, the
variant was visualized by applying the BioEdit tool and annotated against the reference \textit{EFNB1} sequence NM\_004429.4 following the Human Genome Variation Society (HGVS) nomenclature guidelines.

\textbf{Zygosity test}

We used Devyser Complete v2 kit (Devyser, Sweden) following the manufacturer's protocol to analyze the twin sisters' zygosity status (patient 5 & 6). The kit contains 33 short tandem repeats (STR) markers localized on 13, 18, 21, X and Y chromosomes.

\textbf{XCI assay}

We performed XCI assay based on the methylation specificity of restriction enzymes at STR located within the \textit{AR} gene (patient 5 & 6). We used \textit{HpaII} restriction endonuclease that presents a particular activity only on unmethylated gDNA. 100 ng of gDNA was digested with either 20 U \textit{RsaI} (reference sample) or a mixture of enzymes, i.e. 20 U \textit{RsaI} and 20 U \textit{HpaII} (Thermo Fisher Scientific). After incubation and inactivation of enzymes we performed PCR amplification. The reaction was set up using FAM-labeled primers 5′-TCCAGAATCTGTTCCAGAGCGTGC-3 (forward), 5′-GCTGTGAAGGTTGCTGTTCCTCAT-3 (reverse) as described by Janczar et al. (11,12). We separated the PCR products on an ABI 3130 DNA sequencing analyzer (Applied Biosystems) and analyzed in GeneMarker software v2.7.0 (SoftGenetics). The area under the peak was calculated and normalized (11).

\textbf{Face2Gene analysis}

We used Face2Gene tool to test whether the craniofacial symptoms present in twin patients 5 & 6 were characteristic of CFNS. Face2Gene's inbuilt algorithm quantifies facial gestalt based on hundreds of photographs of specific and confirmed syndrome patients. As a result, a list of possibly matching syndromes is created and ranked with a score called Gestalt Score.

\textbf{Abbreviations}

ACMG – American College of Medical Genetics and Genomics, CFNS – craniofrontonasal syndrome, CS – craniosynostosis, NGS – next-generation sequencing, XCI – X chromosome inactivation

\textbf{Declarations}

\textbf{Availability of data and materials}

The datasets for this article are not publicly available due to concerns regarding participants' patients anonymity. Requests to access the datasets should be directed to the corresponding author.

\textbf{Ethics statement}

According to the Good Clinical Practice and Polish law, the studies involving human participants were reviewed and approved by the Bioethics Committee at Poznan University of Medical Sciences (no. 741/17 and 742/17). All patients and their parents agreed to participate in this study. Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin. Written informed consent was obtained from the minor(s)' legal guardian/next of kin to publish any potentially identifiable images or data included in this article.
Authors’ contributions

A.J., A.J.-T., M.J., E.O. recruited and clinically diagnosed the patients; A.J. and E.B.-O. designed the study and wrote the manuscript; E.B.-O. performed, analyzed the molecular data and prepared figures, and tables, P.G. performed a part of in silico analysis, M.P. and M.B. participated in a part of the experimental procedures. All authors have read and approved the final manuscript.

Funding

This work was supported by the Poznan University of Medical Sciences grant – 502-14-11261860-41259 to E.B.-O., the Polish National Science Centre grants 2016/23/N/NZ5/02577 to E.B.-O., 2016/22/E/NZ5/00270 to A.J.

Acknowledgements

We are grateful to the patients and their parents for participating in this study.

Conflict of interest

The authors declare that they have no conflict of interest.

Web resources

ClinVar, https://www.ncbi.nlm.nih.gov/clinvar/

Face2Gene, https://www.face2gene.com/

gnomAD, https://gnomad.broadinstitute.org/

HGMD, http://www.hgmd.cf.ac.uk/ac/index.php

OMIM, https://www.omim.org/

Primer3, http://bioinfo.ut.ee/primer3-0.4.0/

Varsome: https://varsome.com/

References

1. Cohen MMJ. Craniofrontonasal dysplasia. Birth Defects Orig Artic Ser. 1979;15(5B):85–9.

2. Twigg SRF, Matsumoto K, Kidd AMJ, Goriely A, Taylor IB, Fisher RB, et al. The origin of EFNB1 mutations in craniofrontonasal syndrome: frequent somatic mosaicism and explanation of the paucity of carrier males. Am J Hum Genet. 2006 Jun;78(6):999–1010.

3. Twigg SRF, Babbs C, van den Elzen MEP, Goriely A, Taylor S, McGowan SJ, et al. Cellular interference in craniofrontonasal syndrome: males mosaic for mutations in the X-linked EFNB1 gene are more severely affected than true hemizygotcs. Hum Mol Genet. 2013 Apr;22(8):1654–62.

4. Van Den Elzen MEP, Twigg SRF, Goos JAC, Hoogeboom AJM, Van Den Ouweland AMW, Wilkie AOM, et al. Phenotypes of craniofrontonasal syndrome in patients with a pathogenic mutation in EFNB1. Eur J Hum Genet [Internet]. 2014;22(8):995–1001. Available from: http://dx.doi.org/10.1038/ejhg.2013.273
5. Wieacker P, Wieland I. Clinical and genetic aspects of craniofrontonasal syndrome: Towards resolving a genetic paradox. Mol Genet Metab. 2005;86(1–2):110–6.

6. Compagni A, Logan M, Klein R, Adams RH. Control of skeletal patterning by ephrinB1-EphB interactions. Dev Cell. 2003 Aug;5(2):217–30.

7. Niethamer TK, Teng T, Franco M, Du YX, Percival CJ, Bush JO. Aberrant cell segregation in the craniofacial primordium and the emergence of facial dysmorphology in craniofrontonasal syndrome. PLoS Genet. 2020 Feb;16(2):e1008300.

8. Shotelersuk V, Kamolvisit W, Rojvachiranonda N, Suphapeetiporn K, Porntaveetus T, Shotelersuk V. Severe craniofrontonasal syndrome in a male patient mosaic for a novel nonsense mutation in EFNB1. Eur J Med Genet. 2020 Jun;63(6):103924.

9. Niethamer TK, Teng T, Franco M, Du YX, Percival CJ, Bush JO. Aberrant cell segregation in the craniofacial primordium and the emergence of facial dysmorphology in craniofrontonasal syndrome. PLoS Genet. 2020 Feb;16(2):e1008300.

10. Bukowska-Olech E, Sowińska-Seidler A, Łojek F, Popiel D, Walczak-Sztulpa J, Jamsheer A. Further phenotypic delineation of the auriculocondylar syndrome type 2 with literature review. J Appl Genet [Internet]. 2020; Available from: https://doi.org/10.1007/s13353-020-00591-3.

11. Waterhouse A, Bertoni M, Bienert S, Studer G, Taurielo G, Gumienny R, et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 2018 Jul;46(W1):W296–303.

12. Izumi K, Hayashi D, Grochowski CM, Kubota N, Nishi E, Arakawa M, et al. Discordant clinical phenotype in monozygotic twins with Alagille syndrome: Possible influence of non-genetic factors. Am J Med Genet A. 2016 Feb;170A(2):471–5.

13. Li L, Huang L, Lin S, Luo Y, Fang Q. Discordant phenotypes in monozygotic twins with 16p11.2 microdeletions including the SH2B1 gene. Am J Med Genet A. 2017 Aug;173(8):2284–8.

14. Dunkerton S, Field M, Cho V, Bertram E, Whittle B, Groves A, et al. A de novo Mutation in KMT2A (MLL) in monozygotic twins with Wiedemann-Steiner syndrome. Am J Med Genet A. 2015 Sep;167A(9):2182–7.

15. Wieland I, Makarov R, Reardon W, Tinschert S, Goldenberg A, Thierry P, et al. Dissecting the molecular mechanisms in craniofrontonasal syndrome: differential mRNA expression of mutant EFNB1 and the cellular mosaic. Eur J Hum Genet. 2008 Feb;16(2):184–91.

16. Abellaoui A, Ehli EA, Hottenga J-J, Weber Z, Mbarek H, Willemsen G, et al. CNV Concordance in 1,097 MZ Twin Pairs. Twin Res Hum Genet Off J Int Soc Twin Stud. 2015 Feb;18(1):1–12.

17. Nishimura F, Bundo M, Ueda J, Yoshikawa A, Nishimura F, Sasaki T, et al. Identification of somatic mutations in monozygotic twins discordant for psychiatric disorders. npj Schizophrenia [Internet]. 2018;4(1):7. Available from: https://doi.org/10.1038/s41537-018-0049-5.
20. Fan X, Ping L, Sun H, Chen Y, Wang P, Liu T, et al. Whole-Exome Sequencing of Discordant Monozygotic Twin Families for Identification of Candidate Genes for Microtia-Atresia. Front Genet. 2020;11:568052.

21. Körber L, Schneider H, Fleischer N, Maier-Wohlfart S. No evidence for preferential X-chromosome inactivation as the main cause of divergent phenotypes in sisters with X-linked hypohidrotic ectodermal dysplasia. Orphanet J Rare Dis. 2021 Feb;16(1):98.

**Figures**

Patient 5 and patient 6 are monozygotic twin sisters with a highly variable clinical presentation of CFNS. While patient 5 presents with typical facial features of CFNS (a-d), patient 6 (e) shows relatively mild phenotype (see Table 1 for details) that is not suggestive for CFNS. Partial skin syndactyly of toes 3-4 of the right foot and toes 2-
3 of the left foot diagnosed in patient 5 (d). The family pedigree (f). The analysis of relatives was not possible because twins were adopted.

Figure 2

Targeted next-generation sequencing results (a). Pathogenic single nucleotide variants in the EFNB1 gene were visualized using Integrative Genomics Viewer (IGV) – c.35G>A p.(Trp12*) in patient 1 and c.628G>T p.(Glu210*) in patient 5. Targeted Sanger sequencing of the EFNB1 gene results (b). Pathogenic single nucleotide variants in the EFNB1 gene were visualized using BioEdit tool – c.191G>T p.(Cys64Phe) in patient 2, c.216del p. (Tyr73Metfs*86) in patient 3, c.451G>A p.(Gly151Ser) in patient 4 and c.628G>T p.(Glu210*) in patient 6.
Figure 3

Schematic view of the EFNB1 gene and ephrin-B1 structure with an overview of all single nucleotide variants identified in this study (a). Ephrin-B1 is encoded by the EFNB1 gene and consists of four structural units, such as a signal peptide, ephrin, transmembrane and cytoplasmatic domains. Similarly, to our results, the great majority of all pathogenic variants occurs within the first three exons and are expected to disrupt the signal peptide and the ephrin domain of ephrin-B1. The 3D visualization of both wild type and mutated missense alterations in the ephrin-B1 made applying SWISS-MODEL, i.e. p.(Cys64Phe) and p.(Gly151Ser), i.e. p.(Cys64Phe) (b) and p. (Gly151Ser) (c).

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryFigure131.03.2021.tif
- SupplementaryTable1.docx